Clinical Medicine Frontiers is an international, peer-reviewed open access journal dedicated to advancing research the field of clinical medicine. The journal provides a rapid publication process to ensure wide dissemination of high-quality articles to scientists, professionals, and interested individuals worldwide. Our goal is to serve as an efficient, reliable, and trusted platform for scholars and readers, publishing cutting-edge research in the field.
Abstract: Objective: To systematically evaluate the health economics research status of the treatment of liver cancer in Chinese groups. Methods: Taking "China", "liver cancer", "treatment" and "health economics evaluation" as the theme headings, the computer searched CNKI, WanFang data, VIP, PubMed, EMbase, The Cochrane Library and Web of Science to collect health economics research literature on the treatment of liver cancer in China, and the search period was all established until October 1, 2022. Two review authors independently selected studies for inclusion based on screening criteria; The risk of bias of each study was evaluated, and the research objects, evaluation models, evaluation methods, research perspectives, etc. were qualitatively analyzed; For comparison, medical costs are converted and discounted at a discount rate of 5% to the RMB level in 2021; For studies that evaluated the incremental cost-effectiveness ratio (ICER), further statistics were performed to analyze whether it had a cost effect. Results: A total of 28 studies were included, including 14 Chinese and 14 English studies. 60.7% of the study subjects were patients with intermediate and advanced liver cancer, 32.1% were patients with early and intermediate liver cancer, 7.1% were not limited to staging, and 10.7% of the studies evaluated the traditional Chinese medicine program. 92.9% of studies used cost-effect analysis and 7.1% used least-cost analysis; 46.4% (13/28) of studies used the Markov model, 7.1% used the partition survival model, and 46.4% did not establish an economic model; In the study reporting ICER, the median incremental cost was ¥211,611.07, the median ICER was ¥554,915.14, and the median quality-adjusted life years were 0.875 QALYs. Conclusion: At present, the treatment of liver cancer in China is mainly surgery, intervention, radiotherapy and chemotherapy, and there are still limitations of less consideration of indirect medical costs, and the evaluation of traditional Chinese medicine programs may be a hot research direction.Abstract: Objective: To systematically evaluate the health economics research status of the treatment of liver cancer in Chinese groups. Methods: Taking "China", "liver cancer", "treatment" and "health economics evaluation" as the theme headings, the computer searched CNKI, WanFang data, VIP, PubMed, EMbase, The Cochrane Library and Web of Science to collect...Learn More
Abstract: Objective: To report the primary response to chemoradiotherapy induced dermatitis and/or oral mucositis. Methods: In this prospective cohort, 37 patients who underwent concurrently or sequentially chemotherapy and/or anti-cancer drug therapy received personalized multiple plant oil treatment when they suffered the dermatitis and/or oral mucositis. The grade of toxicities and the recovery was evaluated with the criteria of Common Terminology Criteria for Adverse Events (CTCAE) 5.0. Results: For all the patients, the median age was 51.5 and the male was 26 patients (70.3%). 14 (37.8%) and 8 (21.6%) patients respectively received chemotherapy and radiotherapy alone, and 15 (40.5%) had chemoradiotherapy. Head and neck, gastrointestinal, breast and the other cancer were 15 (40.5%), 13 (35.1%), 15 (40.5%), 6 (16.2%) and 3 (8.1%) respectively. Three and 11 patients suffered grade 3 and 2 radiation induced dermatitis respectively. Seven, five and seven patients did grade 3, 2 and 1 of oral mucositis respectively. Three and five patients had grade 3 and 2 of hand and foot syndrome. For dermatitis, oral mucositis, hand and foot syndrome, the median recovery time was 5, 5-10 and 8-10 days. Conclusion: For patients suffering from the chemoradiotherapy induced skin and/or mucosal toxicities, the multiple plant oils could be effective. All the patients tolerate well and the median recovery time were 5-10 days.Abstract: Objective: To report the primary response to chemoradiotherapy induced dermatitis and/or oral mucositis. Methods: In this prospective cohort, 37 patients who underwent concurrently or sequentially chemotherapy and/or anti-cancer drug therapy received personalized multiple plant oil treatment when they suffered the dermatitis and/or oral mucositis. ...Learn More
Abstract: Objective: To analyze the anesthetic effect of internal thoracoscopic surgery with sufentanil and remifentanil target-controlled infusion intravenous anesthesia. Methods: Eighty patients who underwent internal thoracoscopic examination at the endoscopy center of our hospital were selected for analysis. The selected 80 patients were grouped by random number table. 40 patients received sufentanil target-controlled infusion vein. Anesthesia was used as the study group. The remaining 40 patients received remifentanil target-controlled infusion intravenous anesthesia as a control group, and the anesthetic effects of the two groups of patients after receiving different anesthetic target-controlled infusion measures were compared. Results: After the two groups of patients received different anesthetic drug target-controlled infusion measures, the circulation was stable during the operation. The difference of pain visual analog scores was not obvious 30 minutes after the end of the operation. There was a significant difference in the wake-up time between the two groups. There was no significant difference in the incidence of adverse reactions between the two groups after surgery. Conclusions: In patients with clinical thoracoscopic surgery, remifentanil and remifentanil can be used for target-controlled infusion intravenous anesthesia, but patients in the remifentanil group can wake up more quickly and can be promoted and applied.Abstract: Objective: To analyze the anesthetic effect of internal thoracoscopic surgery with sufentanil and remifentanil target-controlled infusion intravenous anesthesia. Methods: Eighty patients who underwent internal thoracoscopic examination at the endoscopy center of our hospital were selected for analysis. The selected 80 patients were grouped by rando...Learn More
